Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Wyeth Prepares Effexor For Second-Quarter Challenge From Lilly Cymbalta

  • News

Executive Summary

Wyeth expects Lilly's Cymbalta to enter the market as a competitor to Effexor during the second quarter, the company said during a Jan. 28 earnings call

You may also be interested in...



Lilly GMPs Will Not Deter Product Rollout, Firm Says

The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program

Lilly GMPs Will Not Deter Product Rollout, Firm Says

The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program

Lilly Forteo “Customer Care” Program Provides One Month Of Therapy Free

Lilly is providing one month of its osteoporosis therapy Forteo free to patients as part of the Forteo Customer Care program

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By